Illustrative only
GeographyUS
Addressable patients25,000
Probability of success, base35%
Potential launchQ3 ’31
Peak sales · Base case$150m
Risk-adjusted peak sales$53m
Development spend, next 12 months1%
Market attractiveness
- Market size1.5 / 5
- Unmet need3 / 5
- Competitive headroom2 / 5
- Pricing potential4.5 / 5
Why it sits where it does
The best pricing potential in the set, on the smallest addressable population.
0–5 = attractiveness. A crowded market or a high bar scores low.
Assessment summary
Next decision
Phase II readout 2029 – PoS 35% → 55% if positive.
The nine modules behind this summary are built out on Heart failure (HFrEF) in this preview.
Open the HFrEF workspace